The genetic basis of kidney cancer [electronic resource] / W. Marston Linehan.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Kidney in health and disease: ; Henry Stewart talksBiomedical & life sciences collection. Molecular genetics of human disease: Publisher: London : Henry Stewart Talks, 2014Description: 1 online resource (1 streaming video file (52 min.) : color, sound)Subject(s): Cancer -- Genetic aspects | Kidneys -- Cancer | Kidneys -- Diseases -- Genetic aspects | Medical genetics | Renal cell carcinoma | Carcinoma, Renal Cell | Genetics, Medical | Kidney Diseases -- Genetics | Kidney Neoplasms | Metabolic DiseasesOnline resources: Click here to access online | Series (Molecular genetics of human disease) | Series (Kidney in health and disease) Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: Renal carcinoma -- Stage I , Stage IV Kidney Cancer -- Human renal epithelial neoplasms -- Loss of alleles in Renal Cell Carcinoma -- Mapping the minimal 3p loss region in Clear Cell Renal Carcinoma -- Studying cancer families to identify renal carcinoma genes -- Identification of kidney cancer genes -- Inherited forms of renal carcinoma -- Clear cell Renal Carcinoma: von Hippel Lindau (VHL) -- VHL gene -- VHL gene localization map -- Germline VHL mutations -- Papillary Renal Carcinoma -- Mouse studies of VHL gene -- VHL gene function -- HIFα -- Downstream effects of VHL mutation -- Targeting VHL/HIF in Clear Cell RCC -- TCGA Clear Cell Kidney Cancer -- Intratumor heterogeneity -- Warburg effect in Clear Cell Kidney Cancer -- Non-Clear Cell RCC -- Locally advanced Kidney Cancer -- Hereditary Papillary Renal Carcinoma (HPRC) -- Inherited Renal Carcinoma -- Type 1 Papillary Renal Carcinoma -- Penetrance of MET mutation H1210R -- MET gene: Type 1 Papillary RCC -- Location of the HPRC gene -- HPRC: Activating mutations in the Tyrosine Kinase domain of MET -- Location of MET mutations in the HPRC patients -- Targeting MET RCC gene pathway -- Potential small molecule target: MET Tyrosine Kinase inhibition -- Foretinib: Dual VEGFR and MET Inhibitor -- MiT Kidney Cancer TFE3, TFEB, MITF -- UOK124, Papillary Kidney Cancer -- UOK124, UOK120, UOK 146 & TFE3 Kidney Cancer -- Inherited Renal Carcinoma Birt-Hogg-Dubé (BHD) -- Birt Hogg Dubé cutaneous manifestations -- Kidney tumors in BHD -- BHD renal tumor pathology -- BHD lung cysts -- Identification of the BHD Gene -- Cutaneous Fibrofolliculomas -- BHD Gene: Chromophobe RCC -- BHD Gene Locus: Chromosome 17 -- BHD Protein Sequence -- FLCN Mutation Spectrum -- Therapeutic Approach: What Kind of Gene is FLCN? -- BHD Gene Analysis in BHD-Associated RCC -- Somatic mutations in renal Tumors from BHD patients -- UOK 257, BHD -/- RCC cell line study -- How does the FLCN gene function? -- Folliculin-FNIP1/2-AMPK interactions -- mTORC1/mTORC2 activation: FLCN-deficient Kidney Cancer -- BHD deletion specifically in the kidney -- BHDf/d/KSPCre mouse kidney study -- Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC) -- HLRCC: cutaneous manifestations, Uterine Leiomyomas -- HLRCC: Papillary Kidney Cancer Type 2 -- Orangophilic nucleoli + Perinucleolar halos -- Fumarate Hydratase gene: HLRCC -- UOK-262 study -- Loss of a Krebs Cycle Enzyme can lead to Kidney Cancer -- Impaired citric acid cycle and "Warburg effect" -- HLRCC-Renal Cancer: glucose-dependent -- PET scan -- HLRCC novel treatment approaches -- Kidney cancer: a metabolic disease.
Access restricted to subscribers.
Mode of access: World Wide Web.